Announcements Trials
Browse Landscape

Status

Completed 59Terminated 10Unknown 7Active not recruiting 5Withdrawn 4Recruiting 4No longer available 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Expanded_access 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Blast Crisis 1

Interventions

nilotinib 3ponatinib 1Transplantation 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × nilotinib × Clear all
NCT04518644 2023-04-28

Nilotinib, for Patients With CML-CP or CML-AP

Novartis

No longer available
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00302016 2011-08-26

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Novartis

No longer available
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00413270 2011-07-13

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Novartis

No longer available
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡